Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (5)

• Takeda's oral TYK2 zasocitinib tops Sotyktu in Phase III showdown FirstWord Pharma · 12h ago
• Takeda’s plaque psoriasis pill beats Bristol Myers’ Sotyktu in Phase 3 Endpoints News · 12h ago
• Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Business Wire · 12h ago
• Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma Dive · 12h ago
• Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown Fierce Biotech · 12h ago

Related trends